ReviewBiochemical pharmacology2009
Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.
Review in Biochemical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 68 citations in OpenAlex.
- Astrocytes and Epilepsy.Neurochemical research · 2021Article
- Intestinal Klebsiella pneumoniae infection enhances susceptibility to epileptic seizure which can be reduced by microglia activation.Cell death discovery · 2021Article
- Genome Editing in Neuroepithelial Stem Cells to Generate Human Neurons with High Adenosine-Releasing Capacity.Stem cells translational medicine · 2018Article
- Nitrobenzylthioinosine mimics adenosine to attenuate the epileptiform discharge of hippocampal neurons from epileptic rats.Oncotarget · 2017Article
- Adenosine APurinergic signalling · 2016Article
- Differential Expression of Adenosine P1 Receptor ADORA1 and ADORA2A Associated with Glioma Development and Tumor-Associated Epilepsy.Neurochemical research · 2016Article
- Adenosine Kinase Inhibition Protects against Cranial Radiation-Induced Cognitive Dysfunction.Frontiers in molecular neuroscience · 2016Article
- The Biochemistry and Epigenetics of Epilepsy: Focus on Adenosine and Glycine.Frontiers in molecular neuroscience · 2016Review
- Does abnormal glycogen structure contribute to increased susceptibility to seizures in epilepsy?Metabolic brain disease · 2015Review
- Adenosine-associated delivery systems.Journal of drug targeting · 2015Review
- A rare complication of a common stress test.Journal of cardiology cases · 2014Article
- Electrophysiology in epilepsy surgery: Roles and limitations.Annals of Indian Academy of Neurology · 2014Article
- Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase.Cerebral cortex (New York, N.Y. : 1991) · 2014Article
- Role of adenosine in the antiepileptic effects of deep brain stimulation.Frontiers in cellular neuroscience · 2014Article
- Sudden unexpected death in Dravet syndrome: respiratory and other physiological dysfunctions.Respiratory physiology & neurobiology · 2013Review
- A ketogenic diet did not prevent effects on the ectonucleotidases pathway promoted by lithium-pilocarpine-induced status epilepticus in rat hippocampus.Metabolic brain disease · 2012Article
- A scaffold as a platform for new therapies?Epilepsy currents · 2012Article
- Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia.The Journal of clinical investigation · 2012Article
- Adenosine release during seizures attenuates GABAA receptor-mediated depolarization.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- Reconstruction of the adenosine system by bone marrow-derived mesenchymal stem cell transplantation.Neural regeneration research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Epilepsy is a common seizure disorder affecting approximately 70 million people worldwide. Current pharmacotherapy is neuron-centered, frequently accompanied by intolerable side effects, and fails to be effective in about one third of patients. Therefore, new therapeutic concepts are needed. Recent research suggests an astrocytic basis of epilepsy, presenting the possibility of novel therapeutic targets. In particular, dysfunction of the astrocyte-controlled, endogenous, adenosine-based seizure control system of the brain is implicated in seizure generation. Thus, astrogliosis - a pathological hallmark of the epileptic brain - is associated with upregulation of the adenosine-removing enzyme adenosine kinase (ADK), resulting in focal adenosine deficiency. Both astrogliotic upregulation of ADK in epilepsy and transgenic overexpression of ADK are associated with seizures, and inhibition of ADK prevents seizures in a mouse model of pharmacoresistant epilepsy. These findings link adenosine deficiency with seizures and predict that adenosine augmentation therapies (AATs) will likely be effective in preventing seizures. Given the wide-spread systemic and central side effects of systemically administered AATs, focal AATs (i.e., limited to the astrogliotic lesion) are a necessity. This Commentary will discuss the pharmacological rationale for the development of focal AATs. Additionally, several AAT strategies will be discussed: (1) adenosine released from silk-based brain implants; (2) adenosine released from locally implanted encapsulated cells; (3) adenosine released from stem cell-derived brain implants; and (4) adenosine augmenting gene therapies. Finally, new developments and therapeutic challenges in using focal AATs for epilepsy therapy will critically be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.